New Drug Derived From Poisonous Weed Treats Prostate Cancer
Researchers have concluded a phase I clinical trial on about 29 patients that have advanced prostate cancer with a new drug. This drug was derived from extracts of a poisonous plant.
The plant grows majorly in the Mediterranean region and it is known to be toxic to animals. The scientists from John Hopkins University and Denmark presented a publication on this in a recent episode of the Science Translational Medicine journal.
The drug made from this poisonous weed was experimented on mice models and have shown great result shrinking cancer cells to about 50% without harming healthy cells. The following are more details on this new experimental drug for prostate cancer:
Scientists have created an experimental drug, derived from a poisonous weed, that can travel harmlessly through the bloodstream until it detects cancer cells and kills them, according to a press release published on Futurity.org.
The drug, G202, shrunk human prostate tumors grown in mice by an average of 50 percent within 30 days – far outperforming docetaxel, a chemotherapy drug currently used against prostate cancer – and was also highly effective against animal models of human breast, kidney and bladder cancers.
The study by scientists from Johns Hopkins University and Denmark was published in the journal Science Translational Medicine.
G202 is derived from Thapsia garganica, a weed that grows in the Mediterranean region that makes a product called thapsigargin, which has been known to be toxic to animals since the time of ancient Greece.
Scientists re-engineered the plant by chemically modifying thapsigargin so that it can travel through the bloodstream without harming healthy blood vessels and tissues. But when G202 encounters cancer tumors, a protein released by the tumors triggers the drug to release cell-killing agents into the tumor and the blood vessels that feed it (as well as other cells nearby).
“The exciting thing is that the cancer itself is activating its own demise,” senior study author John Isaacs of Johns Hopkins said in a press release.
G202 also blocks the function of another protein – known as the SERCA pump – that all cells need to stay alive. Rea searchers said that the blockage of the SERCA pump will make it difficult for tumor cells to become resistant to the drug.
Johns Hopkins physicians have performed phase I clinical trials to assess the safety of the drug and have treated 29 patients with advanced cancer. They are planning a phase II trial to test the drug on patients with prostate and liver cancers. Source.
This is quite an interesting discovery seeing that in the experimental trial, the G202 has shown great potency in treating cancer of the prostate.
It is hoped that with further studies and by validations from successive clinical trials this new drug will get approval from the relevant agencies.
Let’s hope for better treating of cancer patients with this new drug. Nevertheless, this is a plus for prostate cancer research and hopefully men with prostate cancer will have fewer problems to worry about.
This HUGE 4+ Year Old Prostate Cancer Victory Authority Website:
(95% of these 1,000+ Prostate Cancer Articles on this website
are written by our Expert In -house Writers, after lots of research.
The remaining 5% are news articles and videos from relevant sources!)
- Radioisotope Therapy (Ra-223) Treats Bone Metastases Prostate Cancer and Extends Lives
- New Most Powerful Prostate Cancer Drug?
- Cancer Drug New Prostate – New Drug for Prostate Cancer
- Bayer New Prostate Cancer Drug
- Zytiga – New Prostate Cancer Drug From BTG
- New Drug KBU2046 To Contain Metastases of Prostate Cancer
- Wny Johns Hopkins Prostate Cancer Center Is One of the Best Prostate Cancer Centers
- Enzalutamide (MDV3100) – a New Drug from Medivation, can Increase Lifespan for Men with Terminal Prostate Cancer
- Prostate Cancer Drug Ban for NHS To Be Reversed By NICE